AstraZeneca & Emulate to bring advanced organ-on-chip tech in labs
Category: #health  By Dhananjay Punekar  Date: 2018-05-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca & Emulate to bring advanced organ-on-chip tech in labs

AstraZeneca Plc, a biopharma firm headquartered in the UK, has entered into a collaboration with Emulate Inc. to include organ-on-a-chip technology into its R&D program. As per authentic sources, the strategic move is aimed toward marking an upsurge in the technological growth of the firm.

Reportedly, the terms and conditions of the deal state that Emulate’s researchers will be working in co-operation with AstraZeneca scientists at the latter’s IMED (Innovative Medicines & Early Development) labs. For the record, the two firms had begun to jointly work on the technology in 2013.

Lorna Ewart, the head of microphysiological systems at AstraZeneca, has stated that the pharma giant is looking forward to applying the new technology across various areas of treatment and studying the safety & efficiency of the novel medicine candidates. She has further claimed that AstraZeneca has become the first Pharma organization across the globe to set in organ-chips in its own labs.

Medical experts are of the view that the use of new technology by AstraZeneca in its labs will support its R&D decision making processes in the years to come. The technology is speculated to help the firm in accurately judging the adverse as well as non-adverse impact of the drug candidates and gain in-depth insights into the mechanisms of the disease with an objective to enhance the procedure of drug discovery.

Both Emulate Inc. and AstraZeneca are expected to make a combined effort to build the functionalities of three of Emulate’s organ chips that include Glomerulus Kidney-Chip, Lung Tumor-Chip, and Lung-Chip. Geraldine Hamilton, the CEO of Emulate Inc., has announced that the firm aims to promote the new technology and set it as a standard across the pharma sector. Reportedly, the preliminary stage of the deal is likely to utilize Emulate Inc.’s Liver-Chip for safety testing of drug candidates across AstraZeneca’s product pipeline.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...